Cass Entrepreneurship Fund leads £680k investment into HealthTech company Raremark
The Cass Entrepreneurship Fund, the £10m commercial early-stage growth equity Fund at Cass Business School, has led a £680,000 investment round into the innovative health-technology company, Raremark.
Raremark, led by CEO Julie Walters, develops online communities for patient and carer networks in the rare disease space. The company operates a proprietary platform which opens up trusted and verified information, primarily through indexation and summarising of research articles and the latest medical guidelines in a disease area. More than 1 in 20 people will be affected by rare disease in their lifetime, often with chronic or life threatening implications for the sufferer themselves. In many cases there are few meaningful treatments, networks or advocacy groups to drive clinical support. Raremark offers patient support and insight into the latest treatments through development of online communities and dissemination of current research and guidelines.
Cass led the round alongside new and existing Angel investors, including new commitments secured via the SyndicateRoom investment platform.
The Cass Entrepreneurship Fund is based in-house at Cass Business School, and is part of the Peter Cullum Centre for Entrepreneurship. The Fund has a £10m commitment and looks to invest between £100,000 – £500,000, on a commercial basis, into revenue-generating early-stage companies. The Fund, led by Helen Reynolds, invests on a cross-sector basis, and can invest alongside other Funds and Angel investors, or act as sole investor.
The Peter Cullum Centre for Entrepreneurship acts as a hub to support a range of entrepreneurial activities at Cass Business School, led primarily by the Associate Deans of Entrepreneurship, Professors Costas Andriopoulos and Caroline Wiertz.
L – R: Peter Cullum CBE (Chairman, Global Risk Partners), Julie Walters (CEO of Raremark), Helen Reynolds (Investment Director, Cass Entrepreneurship Fund)